Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma

BACKGROUND: Malignant pleural mesothelioma (MPM) is a cancer with a high mortality rate and few therapeutic options. After platinum–pemetrexed combination, no further promising drug seems to be effective. Immune checkpoint inhibitors may have some activity in pretreated patients and no data are avai...

Descripción completa

Detalles Bibliográficos
Autores principales: Canova, S., Ceresoli, G.L., Grosso, F., Zucali, P.A., Gelsomino, F., Pasello, G., Mencoboni, M., Rulli, E., Galli, F., De Simone, I., Carlucci, L., De Angelis, A., Belletti, M., Bonomi, M., D’Aveni, A., Perrino, M., Bono, F., Cortinovis, D.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808442/
https://www.ncbi.nlm.nih.gov/pubmed/36463732
http://dx.doi.org/10.1016/j.esmoop.2022.100644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808442/
https://www.ncbi.nlm.nih.gov/pubmed/36463732
http://dx.doi.org/10.1016/j.esmoop.2022.100644

Ejemplares similares